Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2016

View Archived Issues

Novogen presents TMP3 inhibitors

Tolero initiates first-in-human study of oral TP-0903 in patients with advanced solid tumors

MacroGenics and Synthon Biopharmaceuticals sign antibody-drug conjugate agreement

microRNA-103-1 shows promise as a biomarker of ischemic brain damage

Novel oligomerspecific scFv antibody shows promise in several animal models of amyloidosis

Salmonella meningitis is associated with monocyte infiltration in mouse models

Novel HIV-1-specific bNAb can achieves near pan-neutralization of HIV-1

Chinese scientists patent FGFR inhibitors

Idenix Pharmaceuticals and Southern Research Institute disclose nucleoside derivatives

FDA approves MACI to repair knee cartilage defects

Bristol-Myers Squibb selects CTLA-4 Probody candidate from collaboration with CytomX

Sage begins phase II trials of SAGE-217 in Parkinson's disease and essential tremor

European Commission approves Ferring's Rekovelle

Topline data from phase III PATENCY-1 study of investigational vonapanitase in patients with CKD

Wi2 and Orion announce strategic collaboration in oncology

Centrexion Therapeutics reports topline data from phase IIb study of CNTX-4975

AcelRx Pharmaceuticals submits NDA to FDA for ARX-04

Genticel ends HPV therapeutics program based on phase II trial results

FDA accepts Dimension Therapeutics' IND for DTX-301

BioDelivery Sciences discontinues clonidine topical gel

Topline results from phase III trial of istradefylline in Parkinson's disease

Johnson & Johnson ends transaction discussions with Actelion

First clinical data for DCC-2618

Data reported from phase I study of first-in-class antisense oligonucleotide targeting AR

Phase I study of sEphB4-HSA in advanced solid tumors

First phase I data for of ravoxertinib in advanced solid tumors

Ab Initio Biotherapeutics and Pfizer enter GPCR collaboration

Spotlight Innovation obtains rights to compounds for Zika virus infection

First-in-human data for AstraZeneca's ATR inhibitor AZD-6738

EMA grants UGT1A1 gene therapy orphan designation for Crigler-Najjar syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...